Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBT (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBT for 16 consecutive years, with -$176000.0 as the latest value for Q4 2025.

  • Quarterly EBT fell 104.27% to -$176000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.2 million through Dec 2025, down 879.83% year-over-year, with the annual reading at -$10.2 million for FY2025, 879.83% down from the prior year.
  • EBT for Q4 2025 was -$176000.0 at Anika Therapeutics, up from -$2.2 million in the prior quarter.
  • The five-year high for EBT was $22.9 million in Q4 2023, with the low at -$12.0 million in Q1 2023.
  • Average EBT over 5 years is $37400.0, with a median of -$2.1 million recorded in 2024.
  • The sharpest move saw EBT soared 346.12% in 2022, then plummeted 788.0% in 2025.
  • Over 5 years, EBT stood at -$6.6 million in 2021, then soared by 346.12% to $16.3 million in 2022, then soared by 39.85% to $22.9 million in 2023, then plummeted by 81.99% to $4.1 million in 2024, then tumbled by 104.27% to -$176000.0 in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$176000.0, -$2.2 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.